Valuation: OraSure Technologies, Inc.

Market Cap 277M 244M 227M 208M 391M 26.87B 398M 2.71B 1.06B 13.11B 1.04B 1.02B 45.47B P/E 2026 *
-3.84x
P/E 2027 * -4.91x
Enterprise Value 277M 244M 227M 208M 391M 26.87B 398M 2.71B 1.06B 13.11B 1.04B 1.02B 45.47B EV / Sales 2026 *
2.32x
EV / Sales 2027 * 2.17x
Free-Float
93.62%
Yield 2026 *
-
Yield 2027 * -
1 day+6.33%
1 week+1.77%
Current month-9.64%
1 month-4.95%
3 months+32.13%
6 months+50.94%
Current year+66.53%
1 week 3.7
Extreme 3.705
4.03
1 month 3.7
Extreme 3.705
4.54
Current year 2.33
Extreme 2.33
4.58
1 year 2.08
Extreme 2.08
4.58
3 years 2.08
Extreme 2.08
8.45
5 years 2.08
Extreme 2.08
13.57
10 years 2.08
Extreme 2.08
23.01
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-03
Director of Finance/CFO 54 2022-08-07
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Director/Board Member 59 2020-05-31
Director/Board Member 66 2021-11-07
Director/Board Member 52 2022-06-03
Date Insider Type Main position Quantity % Market Cap.
6/26/26 Free

Director

3,666 0.0053%
6/3/26 Free

Director

46,106 0.0670%
6/3/26 Free

Director

46,106 0.0670%
Change 5-day change 1-year change 3-year change Capi.($)
+6.33%+1.77%+22.12%-10.84% 277M
+0.18%+1.94%-19.93%-11.85% 175B
+0.15%-1.85%-10.87%-7.81% 105B
+1.49%-0.95%+3.96%+58.40% 59.35B
-1.13%-2.60%+26.37%+54.76% 50.71B
-0.12%-4.35%-16.22%-42.24% 42.15B
+1.21%-8.47% - - 31.82B
-1.33%-9.62%-18.45%-46.03% 27.2B
-0.82%-1.92%+56.39%-5.79% 25.11B
+0.03%-4.74%-6.58%-9.24% 20.53B
Average +0.60%-2.90%+4.09%-2.29% 53.76B
Weighted average by Cap. +0.11%-1.51%-5.86%-0.05%

Financials

2026 *2027 *
Net sales 120M 105M 97.8M 89.95M 169M 11.59B 172M 1.17B 456M 5.65B 449M 440M 19.61B 128M 112M 104M 96.07M 180M 12.38B 183M 1.25B 487M 6.04B 480M 470M 20.95B
Net income -73.68M -64.8M -60.2M -55.37M -104M -7.14B -106M -720M -281M -3.48B -277M -271M -12.07B -57.65M -50.7M -47.1M -43.32M -81.24M -5.58B -82.69M -563M -220M -2.72B -216M -212M -9.45B
Net Debt - -
Logo OraSure Technologies, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Employees
500
Date Price Change Volume
26-07-23 US$4.030 +6.33% 449,554
26-07-22 US$3.790 -0.26% 606,388
26-07-21 US$3.800 -1.30% 492,407
26-07-20 US$3.850 -0.52% 189,314
26-07-17 US$3.870 -2.27% 524,026
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.030USD
Average target price
5.000USD
Spread / Average Target
+24.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OSUR Stock